This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 11, Issue 22 pp 10266—10283
Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis
Figure 6. LncRNA FOXD2-AS1 is regarded as a sponge of miR-98-5p. (A) The subcellular localization of FOXD2-AS1 was verified by FISH assay. (B) The binding site of FOXD2-AS1 and miR-98-5p were predicted in the RNA22 website. (C) The binding of FOXD2-AS1 to miR-98-5p was verified by dual luciferase reporter gene assay, miR-98-5p-MUT was MUT plasmid of FOXD2-AS1 and miR-98-5p 3′UTR, and miR-98-5p-WT was WT plasmid of FOXD2-AS1 and miR-98-5p 3′UTR; (D) The binding of FOXD2-AS1 to Ago2 was detected by RIP assay. (E) RNA pull-down assay was used to detect the enrichment of FOXD2-AS1 by miR-98-5p. (F) Expression of miR-98-5p in glioma tumor tissues was detected by RT-qPCR, N = 86; * P < 0.05 vs the oe-NC group, IgG group, Bio-probe NC group or para normal tissues; The data were all measurement data, represented by mean ± standard deviations. The comparison between the two groups was statistically analyzed by independent sample t test, and one-way ANOVA was used in comparisons among multiple groups, and Tukey’s post-hoc test was performed after ANOVA. The experiment was repeated for three times.